The encouraging results of using interferon-beta to increase the activity of CD73, and potentially, decrease the permeability of pulmonary capillaries, showed that among patients with ARDS the treatment increased the CD73 activity almost to three-fold during the dosing period [13]. Here, IFNB1 is linked to acute respiratory distress syndrome.